# psoriasis - claude-opus-4-8

- Benchmark system: raw
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 
- Completion tokens: 
- Reasoning tokens: 
- Total tokens: 
- API requests reported: 
- Elapsed seconds: 132.239
- Final benchmark system: raw; file rank 4/5; original repeat 4; model vendor: Anthropic

---
# Multidimensional Analysis of Psoriatic Lesional Skin Transcriptomics

## 1. Overall Biological Interpretation

The transcriptomic profile of psoriatic lesional skin reveals a highly coordinated inflammatory and hyperproliferative disease state. The upregulated genes demonstrate three dominant and interconnected biological themes: (1) IL-36/IL-17 axis-driven inflammation with prominent innate immune activation, (2) keratinocyte hyperproliferation and altered differentiation characterized by defensive barrier protein expression, and (3) antimicrobial and wound-response programming. The magnitude of expression changes (multiple genes with log2FC > 7) and statistical significance (FDR < 10^-60 for most genes) indicate profound transcriptional reprogramming rather than subtle perturbation. The few downregulated genes (BTC, CYP2W1, LINC02660, LOC107984452, LOC105371988, SAPCD1, SAPCD1-AS1, UGT3A2, WAKMAR1) suggest suppression of homeostatic lipid metabolism and epidermal maintenance programs. Notably, the coherence among cytokines, antimicrobial peptides, barrier proteins, and metabolic enzymes reflects a unified pathological program rather than isolated gene dysregulation.

## 2. Core Biological Programs

### Program 1: IL-36/IL-17-Mediated Inflammatory Signaling
- **Direction**: Markedly upregulated
- **Major supporting genes**: IL36A (log2FC 11.37), IL36G (5.68), IL19 (7.58), IL20 (5.67), IL26 (4.36), IL36RN (3.01), CXCL13 (5.89), TNIP3 (7.28), ZC3H12A (3.85), IRAK2 (2.08)
- **Pathway**: GO:0070498 (Interleukin-36-mediated signaling pathway), GO:0070757 (Interleukin-35-mediated signaling pathway), Reactome R-HSA-448706 (Interleukin signaling)
- **Biological rationale**: The simultaneous upregulation of three IL-36 family members (IL36A, IL36G, and the receptor antagonist IL36RN) alongside IL-17-induced cytokines (IL19, IL20, IL26) represents the core inflammatory circuit of psoriasis. IL-36 cytokines amplify keratinocyte activation and neutrophil recruitment, creating a feed-forward inflammatory loop. TNIP3 and ZC3H12A are negative feedback regulators of NF-κB and inflammatory signaling, suggesting active but insufficient counter-regulatory responses. IRAK2 is a signaling adaptor downstream of IL-1/IL-36 receptors, mechanistically linking these cytokines to downstream transcriptional changes. CXCL13, traditionally a B-cell chemokine, indicates organized lymphoid-like structures in chronic lesions.
- **Strength and limitations**: This is the strongest and most disease-specific signature in the dataset, with multiple independent cytokines showing extreme fold changes and FDR values < 10^-80. These findings are consistent with decades of psoriasis research establishing IL-23/IL-17 and IL-36 pathways as central disease drivers. Limitation: the dataset does not distinguish whether IL-36 upregulation is primary (keratinocyte-intrinsic) or secondary to immune cell infiltration, though tissue context suggests both contribute.

### Program 2: Antimicrobial Defense and Innate Immunity
- **Direction**: Strongly upregulated
- **Major supporting genes**: DEFB4A/DEFB4B (log2FC 11.18/11.03), DEFB103A/DEFB103B (5.76/5.75), S100A7 (7.09), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33), PI3 (9.24), SERPINB3 (6.74), SERPINB4 (9.12), SERPINB13 (3.09)
- **Pathway**: GO:0050829 (Defense response to Gram-positive bacterium), GO:0045087 (Innate immune response), Reactome R-HSA-6803157 (Antimicrobial peptides)
- **Biological rationale**: Beta-defensins (DEFB4A/B, DEFB103A/B) and S100 alarm proteins constitute the antimicrobial peptide (AMP) arsenal of psoriatic epidermis. These are not merely passive barrier components but active participants in inflammation: S100A7/A7A amplify IL-17/IL-36 signaling, S100A8/A12 form calprotectin complexes that promote neutrophil recruitment, and beta-defensins have chemotactic properties for immune cells. The SERPINB family members are cysteine protease inhibitors that regulate keratinocyte death and inflammation. PI3 (elafin/SKALP) is both an antimicrobial peptide and a protease inhibitor, representing a convergent defense mechanism. The coordinated upregulation of multiple AMP families indicates a broad-spectrum antimicrobial response programmed by IL-17 and IL-36 signaling.
- **Strength and limitations**: Strong evidence from multiple independent gene families with consistent direction and extreme fold changes. These genes are established psoriasis biomarkers with known functional roles in disease pathology. Limitation: while AMPs are induced by inflammation, they also perpetuate inflammation through immune cell activation, making it difficult to separate protective versus pathogenic contributions from expression data alone.

### Program 3: Keratinocyte Hyperproliferation and Cell Cycle Activation
- **Direction**: Upregulated
- **Major supporting genes**: RRM2 (log2FC 2.72), CCNE1 (2.56), CDK5R1 (2.35), TPBG (1.86)
- **Pathway**: GO:0000082 (G1/S transition of mitotic cell cycle), KEGG hsa04110 (Cell cycle), Reactome R-HSA-69278 (Cell Cycle, Mitotic)
- **Biological rationale**: RRM2 (ribonucleotide reductase M2) is rate-limiting for DNA synthesis and specifically expressed during S-phase. CCNE1 (cyclin E1) drives G1/S transition. CDK5R1 (p35), while primarily known in neuronal contexts, also regulates keratinocyte proliferation and migration. TPBG (trophoblast glycoprotein/5T4) promotes cell proliferation and is associated with stem-like keratinocyte populations. The proliferation signature is relatively modest compared to the inflammatory signatures (log2FC 1.8-2.7 versus 7-11), suggesting that hyperproliferation, while present, is secondary to inflammation in this transcriptomic hierarchy.
- **Strength and limitations**: Moderate evidence. The proliferation genes are functionally relevant but fewer in number and lower in magnitude compared to inflammatory genes. This program is well-established in psoriasis biology but represents a downstream consequence of cytokine signaling rather than a primary driver. The dataset likely captures a mixture of proliferating basal keratinocytes and terminally differentiating suprabasal cells, potentially diluting proliferation-specific signals.

### Program 4: Altered Epidermal Differentiation and Barrier Remodeling
- **Direction**: Upregulated
- **Major supporting genes**: SPRR2A/2B/2D/2E/2F/2G (log2FC 3.99-7.31), SPRR3 (7.18), LCE3A (8.30), LCE3D (5.31), KRT6A (4.30), GJB2 (4.42), GJB6 (3.02), FABP5 (3.64), AKR1B10 (6.27), AKR1B15 (5.23)
- **Pathway**: GO:0030216 (Keratinocyte differentiation), GO:0031424 (Keratinization), Reactome R-HSA-6805567 (Keratinization)
- **Biological rationale**: Small proline-rich proteins (SPRR2 family, SPRR3) and late cornified envelope proteins (LCE3A, LCE3D) are normally expressed during terminal differentiation but are massively upregulated and spatially disorganized in psoriasis. KRT6A is a stress keratin induced by injury and inflammation, replacing homeostatic keratins. Gap junction proteins (GJB2/connexin 26, GJB6/connexin 30) mediate keratinocyte communication and are dysregulated in hyperproliferative epidermis. FABP5 transports lipophilic molecules and regulates peroxisome proliferator-activated receptor signaling. Aldo-keto reductases (AKR1B10, AKR1B15) metabolize retinoids and lipid aldehydes, altering differentiation programming. Collectively, these changes reflect "regenerative maturation" – rapid but abnormal differentiation that fails to establish proper barrier function.
- **Strength and limitations**: Strong evidence from multiple gene families within the epidermal differentiation complex (EDC) on chromosome 1q21. These changes are histologically validated in psoriatic epidermis. Limitation: distinguishing primary differentiation defects from secondary consequences of sustained inflammation and hyperproliferation is challenging. The SPRR/LCE gene cluster shows copy number variation in the population, which could modulate disease susceptibility but is not captured by expression analysis alone.

### Program 5: Dysregulated Lipid and Xenobiotic Metabolism
- **Direction**: Mixed (primarily suppression)
- **Major supporting genes**: Downregulated: BTC (-4.30), CYP2W1 (-4.70), UGT3A2 (-4.59), SAPCD1 (-2.94); Upregulated: PLA2G4D (4.61), PLA2G4E (2.47), PLBD1 (2.08)
- **Pathway**: GO:0006805 (Xenobiotic metabolic process), GO:0055114 (Oxidation-reduction process), Reactome R-HSA-211859 (Biological oxidations)
- **Biological rationale**: CYP2W1 (cytochrome P450 2W1) and UGT3A2 (UDP glucuronosyltransferase) are phase I and II xenobiotic metabolism enzymes normally expressed in healthy epidermis. Their suppression may impair lipid mediator resolution and contribute to sustained inflammation. BTC (betacellulin) is an EGFR ligand that promotes epithelial maintenance; its downregulation (-4.30 log2FC) contrasts with the hyperproliferative state, suggesting complex EGFR signaling dynamics. SAPCD1 (suppressor APC domain containing 1) regulates lipid metabolism and its suppression could impair barrier lipid synthesis. Conversely, phospholipase A2 family members (PLA2G4D, PLA2G4E) that generate pro-inflammatory lipid mediators (arachidonic acid, eicosanoids) are upregulated, alongside PLBD1 (phospholipase B domain containing 1). This pattern suggests a shift from homeostatic lipid metabolism toward pro-inflammatory lipid mediator production.
- **Strength and limitations**: Moderate-weak evidence. The suppressed metabolic genes show strong statistical significance but are fewer in number. Functional roles in psoriasis are less well-established compared to cytokine and AMP signatures. Limitation: metabolic gene expression may primarily reflect changes in cellular composition (reduced sebocytes, altered keratinocyte maturation states) rather than cell-intrinsic metabolic reprogramming. Validation would require targeted metabolomics and cell-type-specific analysis.

## 3. Key Genes and Interaction Modules

### 1. IL36A, IL36G, and IL36RN (Coordinated IL-36 Axis)
- **Statistical evidence**: IL36A log2FC 11.37 (FDR 1.65×10^-98), IL36G log2FC 5.68 (FDR 1.43×10^-90), IL36RN log2FC 3.01 (FDR 3.85×10^-62)
- **Role**: These genes form a regulatory module within IL-36-mediated inflammation. IL36A and IL36G are agonistic cytokines that signal through the same receptor (IL36R) to activate NF-κB and MAPK pathways in keratinocytes. IL36RN (IL-36 receptor antagonist) is a natural inhibitor that competes for receptor binding. The co-upregulation of agonists and antagonist reflects attempted negative feedback regulation that is insufficient to suppress disease activity.
- **Gene relationships**: Regulatory interaction through receptor competition; pathway co-membership in IL-36 signaling. No direct physical interaction between these secreted cytokines and their receptor antagonist. Clinical evidence: IL-36 signaling inhibition is therapeutic in generalized pustular psoriasis, a severe IL-36-driven disease variant.

### 2. DEFB4A and DEFB4B (Beta-Defensin Duplication Pair)
- **Statistical evidence**: DEFB4A log2FC 11.18 (FDR 2.18×10^-69), DEFB4B log2FC 11.03 (FDR 3.70×10^-71)
- **Role**: These genes encode nearly identical beta-defensin 2 proteins arising from segmental duplication. Both show extreme upregulation and are among the most highly expressed AMPs in psoriasis. They are directly induced by IL-17 and IL-36 through NF-κB and STAT3 signaling. Beyond antimicrobial function, they act as chemokines to recruit CCR6+ immune cells.
- **Gene relationships**: Gene duplication products with >95% sequence identity; functionally redundant. Their coordinate expression is regulated by shared cis-regulatory elements responsive to inflammatory transcription factors. This represents co-regulation rather than interaction.

### 3. S100A7, S100A7A, S100A8, and S100A12 (S100 Alarmin Family)
- **Statistical evidence**: S100A7 log2FC 7.09 (FDR 3.49×10^-62), S100A7A log2FC 9.83 (FDR 9.25×10^-63), S100A8 log2FC 7.73 (FDR 6.05×10^-66), S100A12 log2FC 8.33 (FDR 7.94×10^-97)
- **Role**: S100A7 (psoriasin) and S100A7A are keratinocyte-derived alarmins that amplify inflammatory signaling through RAGE (receptor for advanced glycation end products) and promote chemotaxis. S100A8 and S100A12 are primarily neutrophil- and monocyte-derived and form calprotectin (S100A8/A9) and S100A12 complexes that sequester metal ions, generate oxidative stress, and activate TLR4 and RAGE signaling. Their combined upregulation indicates contributions from both resident keratinocytes and infiltrating myeloid cells.
- **Gene relationships**: Pathway co-membership in RAGE and TLR signaling; S100A8 forms a direct physical interaction (heterodimer) with S100A9 (not in top 100 list). S100A7 and S100A12 do not physically interact but converge on overlapping receptors and downstream pathways. The expression correlation likely reflects co-induction by similar inflammatory stimuli rather than direct regulatory interaction.

### 4. SERPINB3, SERPINB4, and SERPINB13 (Cysteine Protease Inhibitor Cluster)
- **Statistical evidence**: SERPINB3 log2FC 6.74 (FDR 1.36×10^-77), SERPINB4 log2FC 9.12 (FDR 6.68×10^-66), SERPINB13 log2FC 3.09 (FDR 4.09×10^-67)
- **Role**: These serine protease inhibitor family members (despite the name, they inhibit cysteine proteases) protect keratinocytes from cathepsin- and granzyme-mediated cell death during inflammation. SERPINB3 and SERPINB4 inhibit cathepsins K, L, and S and are induced by IL-17 and IL-22. They may contribute to keratinocyte apoptosis resistance and sustained hyperproliferation in psoriasis.
- **Gene relationships**: Gene family members encoded in a cluster on chromosome 18q21.3; likely co-regulated through shared chromatin domains. They have overlapping but non-identical protease specificities. No evidence of direct physical interaction, but functional cooperation in protecting against the same proteolytic threats.

### 5. KYNU (Kynurenine Pathway Enzyme)
- **Statistical evidence**: log2FC 4.42 (FDR 2.00×10^-91)
- **Role**: Kynureninase catalyzes the hydrolysis of kynurenine to anthranilic acid in the tryptophan catabolism pathway. Upregulation may reflect inflammatory induction and altered tryptophan metabolism. Kynurenine pathway metabolites have diverse immunomodulatory effects: some (kynurenine, kynurenic acid) are immunosuppressive through aryl hydrocarbon receptor (AhR) activation, while others (anthranilic acid) may promote inflammation. The biological consequence of KYNU upregulation in psoriasis requires measurement of actual metabolite levels, not just enzyme expression.
- **Gene relationships**: Functions within the tryptophan-kynurenine-NAD+ biosynthetic pathway. Interfaces with AhR signaling, which regulates keratinocyte differentiation and immune responses. Potential indirect regulatory relationship with IL-17 signaling, as IL-17 can modulate tryptophan metabolism.

### 6. GJB2 and GJB6 (Gap Junction Complex)
- **Statistical evidence**: GJB2 log2FC 4.42 (FDR 1.74×10^-86), GJB6 log2FC 3.02 (FDR 1.64×10^-69)
- **Role**: Connexin 26 (GJB2) and connexin 30 (GJB6) form heteromeric gap junction channels in the epidermis, mediating intercellular communication through passage of ions, small metabolites, and second messengers. Their upregulation in psoriasis may reflect both increased keratinocyte density and altered differentiation states. Gain-of-function mutations in GJB2 cause keratoderma, suggesting that overexpression could contribute to abnormal epidermal architecture.
- **Gene relationships**: Direct physical interaction – these connexins form heteromeric hexamers (connexons) that assemble into gap junction channels. This is one of the few gene pairs in this dataset with validated direct protein-protein interaction. They are co-expressed in specific epidermal layers and functionally interdependent.

### 7. WNT5A (Non-Canonical WNT Signaling)
- **Statistical evidence**: log2FC 2.53 (FDR 1.04×10^-67)
- **Role**: WNT5A activates non-canonical WNT signaling pathways (planar cell polarity, WNT/Ca2+) that regulate cell migration, proliferation, and inflammation. In psoriasis, WNT5A promotes keratinocyte proliferation, angiogenesis, and inflammatory cytokine production. It is induced by IL-17 and TNF and contributes to sustained disease activity. WNT5A also promotes macrophage M1 polarization and inflammatory responses, indicating pleiotropic effects on multiple cell types.
- **Gene relationships**: Functions upstream of diverse signaling pathways including Ca2+/NFAT, JNK, and NF-κB. Potential regulatory interaction with IL-17 pathway (IL-17 induces WNT5A; WNT5A may modulate IL-17 responses). No direct physical interaction with cytokines or receptors, but influences their signaling outcomes.

### 8. TNIP3 and ZC3H12A (Negative Feedback Regulators)
- **Statistical evidence**: TNIP3 log2FC 7.28 (FDR 2.82×10^-83), ZC3H12A log2FC 3.85 (FDR 2.49×10^-71)
- **Role**: TNIP3 (TNFAIP3-interacting protein 3) inhibits NF-κB signaling by interacting with TNFAIP3 (A20), a deubiquitinating enzyme that terminates inflammatory signaling. ZC3H12A (MCPIP1/Regnase-1) is an RNase that degrades inflammatory mRNA transcripts including IL-6, IL-12, and IL-17. Their strong upregulation represents transcriptional feedback attempting to limit inflammation. However, their induction is evidently insufficient to suppress disease, possibly due to post-translational inactivation or overwhelming pro-inflammatory signals.
- **Gene relationships**: Both function as negative feedback regulators of NF-κB and inflammatory cytokine signaling, representing pathway co-membership in immune homeostasis networks. TNIP3 physically interacts with TNFAIP3; ZC3H12A does not physically interact with TNIP3 but acts on overlapping inflammatory targets through a different mechanism (mRNA degradation versus ubiquitin editing).

### 9. CD274 (PD-L1)
- **Statistical evidence**: log2FC 3.44 (FDR 1.82×10^-63)
- **Role**: CD274 (PD-L1) is an immune checkpoint ligand that inhibits T cell activation upon binding PD-1 on T cells. Its upregulation in psoriatic lesions likely reflects interferon-γ (IFN-γ) production by infiltrating Th1/Th17 cells, as IFN-γ is the primary inducer of PD-L1. This represents an immune evasion or regulatory mechanism. Paradoxically, immune checkpoint inhibitor therapy can trigger or exacerbate psoriasis, suggesting that baseline PD-L1 expression provides some restraint on pathogenic T cells. The moderate fold change (3.44) indicates partial immune checkpoint activity, insufficient to fully suppress T cell responses.
- **Gene relationships**: Functions in PD-1/PD-L1 immune checkpoint pathway; induced by IFN-γ signaling through JAK-STAT pathway. Represents a regulatory interaction with T cell responses rather than physical interaction with other genes in this dataset.

### 10. KYNU and HPSE (Metabolic-Inflammatory Interface)
- **Statistical evidence**: KYNU log2FC 4.42 (FDR 2.00×10^-91), HPSE log2FC 2.92 (FDR 3.79×10^-78)
- **Role**: Heparanase (HPSE) degrades heparan sulfate in the extracellular matrix, promoting leukocyte infiltration, angiogenesis, and growth factor release. Beyond structural remodeling, HPSE has signaling functions that enhance inflammatory responses. Its co-upregulation with KYNU (kynureninase) suggests coordinated metabolic and structural remodeling to support inflammation. HPSE facilitates tissue infiltration by immune cells whose tryptophan metabolism is altered by KYNU activity, creating a permissive microenvironment for chronic inflammation.
- **Gene relationships**: Indirect relationship through shared induction by inflammatory signals and convergent effects on inflammatory microenvironment. No direct physical or regulatory interaction, but functional cooperation in establishing chronic inflammatory tissue architecture.

## 4. Validation Priorities

### Priority 1: IL-36 Signaling as a Therapeutic Target
- **Classification**: Therapeutic target / Mechanistic hypothesis
- **Rationale**: IL-36A and IL-36G show extreme upregulation (log2FC 11.37 and 5.68), representing the strongest individual signals in the dataset. IL-36 signaling drives keratinocyte activation, neutrophil recruitment, and amplification of IL-17 responses.
- **Current dataset evidence**: Three independent IL-36 family members (agonists and antagonist) are among the top upregulated genes with FDR < 10^-60.
- **External evidence supporting**: (1) Genetic evidence: IL36RN loss-of-function mutations cause generalized pustular psoriasis (GPP), a severe pustular variant. (2) Therapeutic evidence: Spesolimab, an IL-36 receptor antibody, is FDA-approved for GPP and shows efficacy in clinical trials. (3) Mechanistic evidence: IL-36 directly activates keratinocytes and synergizes with IL-17 in mouse models and human keratinocyte cultures. (4) Expression evidence: IL-36 cytokines are consistently elevated in psoriatic skin across multiple studies.
- **External evidence against**: IL-36 blockade is most effective in pustular psoriasis; efficacy in plaque psoriasis (the most common form) is less established and may be more variable. Redundancy with IL-17 signaling may limit therapeutic impact in some patients.
- **Next validation step**: (1) Confirm IL-36 protein expression and localization by immunohistochemistry. (2) Measure IL-36 receptor activation in patient-derived keratinocytes. (3) Test IL-36 receptor antagonists in patient-stratified clinical trials, correlating baseline IL-36 expression with therapeutic response. (4) Mechanistic validation: use IL-36R-blocking antibodies in 3D organotypic skin cultures from psoriasis patients to assess effects on keratinocyte activation and cytokine networks.
- **Evidence classification**: **Supported hypothesis** for plaque psoriasis; **Established evidence** for pustular psoriasis variants.

### Priority 2: DEFB4A/DEFB4B Copy Number Variation and Disease Susceptibility
- **Classification**: Biomarker / Interaction hypothesis
- **Rationale**: DEFB4A/B show extreme upregulation (log2FC ~11) and arise from a genomic region with known copy number variation (CNV). Higher DEFB4 copy number is associated with psoriasis risk in some populations. Testing whether baseline copy number predicts disease severity, treatment response, or clinical subtype could identify patient stratification biomarkers.
- **Current dataset evidence**: Extreme expression changes suggest functional importance, but expression analysis cannot distinguish CNV-driven baseline differences from inflammation-induced changes.
- **External evidence supporting**: (1) Genetic evidence: DEFB4 CNV is associated with psoriasis susceptibility in European and Asian populations (though findings are inconsistent). (2) Functional evidence: Beta-defensins have both antimicrobial and immunomodulatory functions, recruiting CCR6+ Th17 cells. (3) Correlation evidence: DEFB4 expression correlates with disease severity (PASI scores) in some studies.
- **External evidence against**: CNV associations are not consistently replicated across populations, suggesting population-specific genetic architecture or gene-environment interactions. Functional consequences of CNV on protein levels and activity require validation.
- **Next validation step**: (1) Genotype DEFB4 copy number in psoriasis patients and correlate with disease severity, clinical subtype, and treatment response. (2) Measure beta-defensin 2 protein levels in serum and lesional skin, correlating with copy number and inflammation markers. (3) Functionally test whether DEFB4 CNV alters inducibility by IL-17/IL-36 in patient-derived keratinocytes.
- **Evidence classification**: **Exploratory hypothesis** – genetic associations are suggestive but inconsistent; functional consequences of CNV require rigorous validation.

### Priority 3: KYNU and Tryptophan-Kynurenine Pathway as Metabolic Vulnerability
- **Classification**: Mechanistic hypothesis / Therapeutic target
- **Rationale**: KYNU (log2FC 4.42, FDR 2.00×10^-91) is the most significantly upregulated metabolic enzyme. Kynurenine pathway dysregulation links inflammation, immune regulation, and epidermal differentiation through aryl hydrocarbon receptor (AhR) signaling. Manipulating this pathway could offer a mechanisticall
